Health Care • Biotechnology: Pharmaceutical Preparations
$29.21 ▼ -0.78
(-2.60%)
MKT CAP: $2.17B • VOL: 931.3K
52W L $10 52W H $34
CONSENSUS RATING DISTRIBUTION (40 DESKS)
BUY: 30 HOLD: 8
SELL: 2
12M STREET TARGET RANGE
IMPLIED: +14.0%
LOW
$25
MEDIAN
$33
MEAN
$33
HIGH
$40
STREET BS CREDIBILITY SCORE 1Y BACKTESTED
68/100
EMPIRICAL HIT RATE VS SPOT
GRADES WHETHER SELL-SIDE TARGET REVISIONS LEAD OR CHASE XNCR TAPE
XNCR // FIRM-BY-FIRM ANALYST BACKTEST & BS DETECTOR (ANR <GO>)
CURRENT 90D STREET CONSENSUS
| INSTITUTION / ANALYST | ACTION | RATING | TARGET | PRIOR PT | CALL DATE | PX AT CALL | RET SINCE CALL | 1Y ACCURACY | BS GRADE |
|---|---|---|---|---|---|---|---|---|---|
| Morgan Stanley Institutional Equity Desk | REITERATE | OUTPERFORM | $35.34 | $33.59 | 2025-02-14 | $26.58 | +9.9% | 78% | A |
| Goldman Sachs Global Research Sector Coverage | TARGET REV | STRONG BUY | $36.80 | $34.47 | 2025-02-06 | $27.46 | +6.4% | 74% | A |
| J.P. Morgan Securities US Large Cap | REITERATE | BUY | $33.30 | $32.13 | 2025-01-29 | $28.04 | +4.2% | 67% | B |
| Bernstein Autonomous Forensic Coverage | INITIATE | HOLD | $29.79 | — | 2025-01-17 | $28.63 | +2.0% | 61% | B |
| Barclays Capital Americas Research | DOWNGRADE | UNDERPERFORM | $25.70 | $27.75 | 2025-01-09 | $26.00 | -11.2% | 42% | D |
| UBS Investment Bank Institutional Desk | UPGRADE | BUY | $34.76 | $30.38 | 2024-12-18 | $25.41 | +14.9% | 72% | A |
| Citigroup Global Markets Sector Lead | TARGET REV | HOLD | $28.33 | $29.50 | 2024-12-04 | $27.17 | -4.3% | 48% | C |